BofA Securities analyst Alec Stranahan maintains $Intellia Therapeutics (NTLA.US)$ with a buy rating, and adjusts the target price from $65 to $50.
According to TipRanks data, the analyst has a success rate of 42.3% and a total average return of -7.1% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
Despite ongoing uncertainties related to politics and rates, the overall condition of the Biopharma sector is seen as significantly enhanced compared to its 2022 lows. Furthermore, there's a favorable view towards stocks involved in late-stage clinical trials or those in the early launch phase. Yet, there's growing interest among investors towards Phase 1 clinical programs that present derisking data and near-term catalysts.
The fourth quarter is expected to be generally solid for large and mid-cap commercial stage companies in the Biotech sector, supported by seasonal tailwinds. However, the expectations for 2025 might be overly optimistic, with several product launches already factored into valuations and the sustainability of key franchises posing potential challenges.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美银证券分析师Alec Stranahan维持$Intellia Therapeutics (NTLA.US)$买入评级，并将目标价从65美元下调至50美元。
根据TipRanks数据显示，该分析师近一年总胜率为42.3%，总平均回报率为-7.1%。
此外，综合报道，$Intellia Therapeutics (NTLA.US)$近期主要分析师观点如下：
尽管与政治和利率相关的不确定性持续存在，但与2022年的低点相比，生物制药行业的整体状况被视为显著改善。此外，人们对参与后期临床试验或处于早期启动阶段的股票持积极看法。然而，投资者对提供去风险数据和短期催化剂的1期临床项目的兴趣与日俱增。
在季节性利好风的支持下，生物技术领域的大型和中型商业舞台公司预计第四季度将总体保持稳健。但是，对2025年的预期可能过于乐观，一些产品的发布已经计入了估值，关键特许经营权的可持续性构成了潜在的挑战。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
